Todd Watanabe
Chief Executive Officer chez ARCUTIS BIOTHERAPEUTICS, INC.
Fortune : 11 M $ au 31/03/2024
Profil
Todd Franklin Watanabe was the founder of Kanan Therapeutics, Inc. (founded in 2015) where he held the title of Chief Operating Officer from 2015 to 2018.
He is currently the President, Chief Executive Officer & Director at Arcutis Biotherapeutics, Inc. (since 2016) and a Director at Amunix Pharmaceuticals, Inc. (since 2021).
Previously, he worked as the VP-Strategy & Corporate Development at Kythera Biopharmaceuticals LLC from 2013 to 2015.
Mr. Watanabe's education includes undergraduate and graduate degrees from Georgetown University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/03/2024 | 1 105 673 ( 0,98% ) | 11 M $ | 31/03/2024 |
Postes actifs de Todd Watanabe
| Sociétés | Poste | Début |
|---|---|---|
| ARCUTIS BIOTHERAPEUTICS, INC. | Chief Executive Officer | 01/04/2017 |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Director/Board Member | 23/06/2021 |
Anciens postes connus de Todd Watanabe
| Sociétés | Poste | Fin |
|---|---|---|
| Kanan Therapeutics, Inc. | Founder | 01/02/2018 |
| KYTHERA BIOPHARMACEUTICALS INC | Corporate Officer/Principal | 01/11/2015 |
Formation de Todd Watanabe
| Georgetown University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARCUTIS BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Kythera Biopharmaceuticals LLC
 Kythera Biopharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Kythera Biopharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel prescription products for the aesthetic medicine market. The company was founded by Jay Edward Birnbaum, Amit D. Munshi, Nathaniel Eames David, and Keith R. Leonard, Jr. on June 3, 2004 and is headquartered in Westlake, CA. | Health Technology |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Health Technology |
| Kanan Therapeutics, Inc. |
